The Food and Drug Administration today approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain inflammatory diseases. The product (Cyltezo) is approved to treat certain adult and pediatric patients with arthritis or Crohn’s disease, and certain adults with ulcerative colitis or psoriasis. 

Related News Articles

Headline
Ellume has expanded its recall of rapid at-home COVID-19 antigen tests to about 2 million tests, the Food and Drug Administration said in an update this week.…
Headline
Health care providers should not purchase or use certain imported medical gloves from certain companies, which appear to have been reprocessed, cleaned or…
Headline
The Food and Drug Administration today announced a Class 1 recall of battery packs for an intra-aortic balloon pump used with patients undergoing surgery…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…
Headline
The Food and Drug Administration and Magellan Diagnostics Inc. today expanded the ongoing recall of LeadCare II, LeadCare Plus and LeadCare Ultra Blood Lead…
Headline
The Food and Drug Administration today announced it will withdraw regulations for non-drug manufacturers who produced during the COVID-19 public health…